Vaxcyte (NASDAQ:PCVX) Announces Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Vaxcyte (NASDAQ:PCVX) released its quarterly earnings results on Tuesday. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27, Briefing.com reports. During the same period in the prior year, the business posted ($0.91) EPS.

Vaxcyte Stock Down 1.3 %

PCVX traded down $1.37 on Thursday, reaching $102.70. 1,300,292 shares of the company traded hands, compared to its average volume of 839,856. The company has a market cap of $11.46 billion, a P/E ratio of -22.37 and a beta of 1.01. The firm has a fifty day simple moving average of $110.57 and a two-hundred day simple moving average of $86.81. Vaxcyte has a one year low of $46.16 and a one year high of $121.06.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at $37,822,574.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $106.80, for a total value of $854,400.00. Following the transaction, the chief operating officer now owns 205,695 shares in the company, valued at approximately $21,968,226. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 115,098 shares of company stock valued at $12,394,473. 3.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday. Leerink Partners raised their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday. Mizuho boosted their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Finally, Bank of America lifted their target price on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.